IP Library Granted Patent US 7,288,256
Granted Patent B1
US 7,288,256 · App. 08/445,307 · Granted Oct 30, 2007

T cell epitopes of the major allergens from dermatophagoides (house dust mite)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,288,256
App. No.
08/445,307
Granted
Oct 30, 2007
Kind
B1
Abstract

The present invention provides isolated peptides of the major protein allergens of the genus Dermatophagoides . Peptides within the scope of the invention comprises at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen selected from the allergens Der p I, Der p II, Der f I, or Der f II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or of diagnosis of sensitivity to house dust mites in an individual and therapeutic compositions comprising one or more peptides of the invention are also provided.

Claims (8)

1. An isolated peptide selected from the group consisting of:

(a) DP I-25.2 (SEQ ID NO:36);

(b) a portion of DP I-25.2 (SEQ ID NO:36); and

(c) an isolated peptide having an amino acid sequence at least 95% identical to the amino acid sequence of peptide DP I-25.2 (SEQ ID NO:36),

wherein the isolated peptide comprises at least one T cell epitope of a protein allergen of the genus Dermatophagoides.

2. The isolated peptide of claim 1 , wherein said peptide has a positivity index of at least about 150 and a mean T cell stimulation index of at least about 4.0, as determined in a population of individuals sensitive to said protein allergen.

3. A therapeutic composition comprising the peptide of any one of claims 1 or 2 .

4. A method of treating sensitivity to house dust mite allergen in a mammal comprising administering the composition of claim 3 .

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2006
From: HESKA CORPORATION
To: MERCK PATENT GMBH
Reel/Frame 018654/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2006
From: IMMULOGIC PHARMACEUTICAL CORPORATION
To: HESKA CORPORATION
Reel/Frame 018536/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2005
From: IMMULOGIC PHARMACEUTICAL CORPORATION
To: HESKA CORPORATION
Reel/Frame 016301/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2005
From: IMMULOGIC PHARMACEUTICAL CORPORATION
To: HESKA CORPORATION
Reel/Frame 016153/0837 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 1995
From: GARMAN, RICHARD D.; GREENSTEIN, JULIA L.; KUO, MEI-CHUNG; ROGERS, BRUCE L.; FRANZEN, HENRY M.; CHEN, XIAN; EVANS, SEAN; SHAKED, ZE'EV
To: IMMULOGIC PHARMACEUTICAL CORPORATION
Reel/Frame 007651/0490 →